Triptorelin
Also known as: GnRH agonist, Decapeptyl, Trelstar, D-Trp6-LHRH
Triptorelin is a prescription medication. For research and informational purposes only.
Overview
Potent synthetic GnRH agonist approximately 100× more potent than native GnRH. Used clinically for prostate cancer, endometriosis, and precocious puberty via sustained suppression. A single low dose (100mcg IM) is studied as a 'PCT restart' strategy that exploits the initial LH/FSH flare before receptor desensitization sets in.
Research Summary
Triptorelin produces a biphasic response: an initial agonist surge of LH and FSH (the 'flare effect') followed by complete pituitary desensitization with continued use. The single-dose PCT protocol leverages only the initial flare to jumpstart testosterone production. Clinical data supports LH surges of 10–20× baseline within hours of the first dose.
Dosing Range
low
50mcg
moderate
100mcg
high
200mcg
Units: mcg · Frequency: Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical)
Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.
Administration Routes
Reconstitution Notes
Reconstitute with sterile water. Use promptly — single-dose vials preferred for PCT applications. For depot formulations (sustained release), follow manufacturer protocol.Step-by-step reconstitution guide →
Supplies you'll need
Affiliate links — Research Stack may earn a small commission at no extra cost to you.
Reported Side Effects
- Initial testosterone surge followed by suppression (with repeated dosing)
- Hot flashes
- Decreased libido
- Bone density loss (long-term repeated dosing)
- Mood changes
- Injection site reactions
Research Papers
2 peer-reviewed sourcesCommunity Experiences
Aggregated from public forums. Anecdotal — not clinical evidence.
Community discussion of single-dose triptorelin PCT protocols and LH/FSH restoration experiences.
View original threadDetailed community debate on triptorelin single-dose PCT vs. SERM-based protocols.
View original threadOverview
Triptorelin is a synthetic nonapeptide analogue of GnRH, with D-tryptophan substituted at position 6 to dramatically increase receptor affinity and metabolic stability. It is approximately 100 times more potent than native GnRH.
Clinically, triptorelin is used as a long-acting GnRH agonist depot to achieve medical castration in prostate cancer, endometriosis, and uterine fibroids — all conditions that are sex hormone-dependent. The paradox of a GnRH agonist producing castrate testosterone levels is explained by its biphasic pharmacology.
Mechanism
The Biphasic Response
Phase 1 — Flare (first 3–7 days) Triptorelin initially activates GnRH receptors strongly → massive LH and FSH surge → testosterone spikes 3–5× above baseline. This is the "testosterone flare."
Phase 2 — Desensitization (continued use) Continuous receptor occupancy (unlike pulsatile native GnRH) → GnRHR internalization and downregulation → loss of LH/FSH secretion → castrate testosterone levels within 2–4 weeks.
Single-Dose PCT Strategy
The research community has developed a protocol exploiting only Phase 1:
- A single intramuscular dose of 100mcg is administered
- This triggers a robust LH/FSH surge within hours
- Without repeat dosing, the pituitary recovers normal sensitivity
- The LH surge stimulates Leydig cells to resume testosterone production
- SERM (tamoxifen or clomiphene) may be combined to block estrogen feedback during recovery
Triptorelin vs. Gonadorelin for HPG Restart
| Parameter | Triptorelin (single) | Gonadorelin (ongoing) | |-----------|----------------------|-----------------------| | Mechanism | One-time LH flare | Ongoing pulsatile stimulation | | Frequency | Single dose | 2–3x/week | | Risk | Potency error (over-suppression) | Requires consistent adherence | | Use case | PCT hard restart | TRT testicular maintenance |
Important Safety Consideration
Because triptorelin is highly potent, dosing accuracy is critical. An accidental second dose shortly after the first could initiate Phase 2 desensitization and worsen the suppression it was intended to reverse. Single-dose vials and careful documentation of administration are essential in research protocols.
Related Performance Peptides
ACE-031
PerformanceACVR2B-Fc · ActRIIB-Fc fusion protein
Soluble form of activin type IIB receptor (ActRIIB-Fc fusion protein) that acts as a myostatin and activin trap. Blocks…
CJC-1295
PerformanceCJC-1295 DAC · CJC-1295 without DAC (Mod GRF 1-29)
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release gro…
CJC-1295 / Ipamorelin Stack
PerformanceCJC-1295 Ipamorelin · Mod GRF 1-29 Ipamorelin
The CJC-1295 (without DAC) and Ipamorelin combination is the most widely researched and community-validated growth hormo…